Growth factors as treatment options for intestinal inflammation.
On the basis of several studies that have been completed to date, some growth factors appear promising for the treatment of inflammatory bowel disease: keratinocyte-like growth factor-2 (KGF-2), epidermal growth factor (EGF) enemas used in combination with oral mesalamine, somatropin (human growth hormone), and sargramostim (recombinant human GM-CSF). The results of these studies are highlighted and suggest that new insights into the regulation of intestinal immunity may provide effective synergistic or single-agent treatment alternatives to immunosuppression for inflammatory bowel disease. These data focus on the reparative components of mucosal homeostasis.
Dieckgraefe
Brian K
BK
Division of Gastroenterology, Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA. dieck@im.wustl.edu
Korzenik
Joshua R
JR
Anant
Shrikant
S
D000818:Animals; D003093:Colitis, Ulcerative / Q000628:therapy*; D051526:Fibroblast Growth Factor 10 / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006133:Growth Substances / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D023421:Models, Animal; D051381:Rats; D011917:Rats, Inbred Lew
D051526:Fibroblast Growth Factor 10; D006133:Growth Substances; D016178:Granulocyte-Macrophage Colony-Stimulating Factor